845 related articles for article (PubMed ID: 19573639)
1. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
2. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
Liu J; Yu Q; Stone GW; Yue FY; Ngai N; Jones RB; Kornbluth RS; Ostrowski MA
Vaccine; 2008 Jul; 26(32):4062-72. PubMed ID: 18562053
[TBL] [Abstract][Full Text] [Related]
3. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
4. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
Li W; Li S; Hu Y; Tang B; Cui L; He W
Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
[TBL] [Abstract][Full Text] [Related]
5. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
7. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination.
Du X; Zheng G; Jin H; Kang Y; Wang J; Xiao C; Zhang S; Zhao L; Chen A; Wang B
J Gene Med; 2007 Feb; 9(2):136-46. PubMed ID: 17310492
[TBL] [Abstract][Full Text] [Related]
8. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant effect of plasmid vector-expressed OX40L on candidate DNA vaccine against type B heptatitis].
Du X; Kang Y; Wang X; Wang J; Zhao G; Wang B
Wei Sheng Wu Xue Bao; 2009 Mar; 49(3):357-62. PubMed ID: 19623960
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
12. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
13. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
Marovich MA; Mascola JR; Eller MA; Louder MK; Caudrelier PA; El-Habib R; Ratto-Kim S; Cox JH; Currier JR; Levine BL; June CH; Bernstein WB; Robb ML; Schuler-Thurner B; Steinman RM; Birx DL; Schlesinger-Frankel S
J Infect Dis; 2002 Nov; 186(9):1242-52. PubMed ID: 12402193
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
15. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
[TBL] [Abstract][Full Text] [Related]
16. Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants.
Xiao C; Jin H; Hu Y; Kang Y; Wang J; Du X; Yang Y; She R; Wang B
Antiviral Res; 2007 Oct; 76(1):11-20. PubMed ID: 17540462
[TBL] [Abstract][Full Text] [Related]
17. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
18. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
19. Activated T cells express the OX40 ligand: requirements for induction and costimulatory function.
Mendel I; Shevach EM
Immunology; 2006 Feb; 117(2):196-204. PubMed ID: 16423055
[TBL] [Abstract][Full Text] [Related]
20. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
Kanagavelu SK; Snarsky V; Termini JM; Gupta S; Barzee S; Wright JA; Khan WN; Kornbluth RS; Stone GW
Vaccine; 2012 Jan; 30(4):691-702. PubMed ID: 22146759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
